Bridger Capital Adds To Atara Biotherapeutics

Roberto Mignone's hedge fund firm Bridger Capital has filed a 13G with the SEC regarding its stake in Atara Biotherapeutics (ATRA).  Per the filing, Bridger now owns 5.2% of the company with over 1.52 million shares.

This means Bridger has boosted its position size by 725,870 shares since the end of 2016.  The filing was made due to activity on April 11th.

Per Google Finance, Atara Biotherapeutics is "a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV. "

Baupost Group Discloses Paratek Pharmaceuticals Stake

Seth Klarman's hedge fund firm Baupost Group has filed a 13G with the SEC regarding shares of Paratek Pharmaceuticals (PRTK).  Per the filing, Baupost now owns 12.04% of the company with over 1.7 million shares.

This is a newly disclosed equity position for the firm and the filing was required due to activity on October 31st.


The firm has been active in that sector recently.  Back in early November, Baupost also disclosed new positions in Atara Biotherapeutics (ATRA) and Forward Pharma (FWP), per 13G's filed with the SEC.

Per Google Finance, Paratek Pharmaceuticals is "a specialty pharmaceutical company focused on the development and commercialization of products that address therapeutic needs in the field of neuroscience."